Table 1.

Morphometric data from mice receiving 4 wk of imatinib treatment beginning at day 90^a

Parameter	WT	TSLP-Control	TSLP-Imatinib
% GTA occupied by silver-stained matrix	6.25 ± 0.95	14.27 ± 0.11b	6.79 ± 0.66d
Cell number/glomerular cross-section	32.70 ± 1.34	38.13 ± 0.69c	38.70 ± 1.91c
% GTA occupied by collagen type IV–stained matrix	10.47 ± 0.43	17.06 ± 1.48b	13.46 ± 0.68e
% GTA occupied by α-SMA–expressing cells	0.65 ± 0.06	1.76 ± 0.17b	1.26 ± 0.24f
GTA occupied by Mac-2–expressing cells (μm2)	4.98 ± 1.18	61.36 ± 11.89b	142.33 ± 51.98c,e

^aData are means ± SEM.

^bP < 0.001,

^cP < 0.01 versus WT mice.

^dP < 0.001,

^eP < 0.05,

^fP < 0.01 versus control TSLP-Tg mice.